Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Cellectis    ALCLS   FR0010425595

CELLECTIS

(ALCLS)
  Report
Real-time Quote. Real-time Euronext Growth Paris - 01/15 11:00:49 am
25.5 EUR   -0.78%
01/14European ADRs Climb Higher in Thursday Trading
MT
01/13European ADRs Move Lower in Wednesday Trading
MT
01/11European ADRs Move Sharply Lower in Monday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cellectis : Corporate Presentation November 2020

11/13/2020 | 07:27am EST

COMMITMENT TO A CURE

cellectis.com

FORWARD-LOOKING STATEMENTS

This presentation contains "forward-looking" statements that are based on our management's current expectations and assumptions and on information currently available to management.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

The risks and uncertainties include, but are not limited to the risk that the preliminary results from our product candidates will not continue or be repeated, the risk that our clinical trials will not be successful. The risk of not obtaining regulatory approval to commence clinical trials on additional UCART product candidates,

the risk that any one or more of our product candidates will not be successfully developed and commercialized.

Further information on the risk factors that may affect company business and financial performance, is included in our annual report on form 20-F and the financial report (including the management report) for the year ended December 31, 2019 and subsequent filings Cellectis makes with the Securities and Exchange Commission from time to time.

Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Cellectis proprietary information. Not to be copied, distributed or used without Cellectis' prior written consent.

P2

WRITING THE HISTORY OF ALLOGENEIC CAR T-CELLS

20 years

8 years

6 clinical trials

of expertise in

of experience in allogeneic

ongoing as of 2020;

gene editing

CAR-T manufacturing

3 Cellectis-sponsored

3 partnered

INVENTORS / PIONEERS OF GENE EDITING & ALLOGENEIC CAR T-CELLS

In 2012 . .

Mission to develop allogeneic CAR T-cells begins

In 2015 . .

First-in-man compassionate use of an allogeneic CAR-T product candidate occurs

P3

ADVANTAGES OF ALLOGENEIC VS. AUTOLOGOUS CAR-T

Autologous process:

Manufacturing variability + several weeks before treatment is available

1.

2.

3.

4.

CANCER TREATMENT

CANCER

MANUFACTURING OF A

INDIVIDUAL CAR-T

DECISION

PATIENT APHERESIS

SINGLE PATIENT

THERAPY

PRODUCT

Allogeneic process:

Consistent manufacturing + quality

Immediate treatment

HEALTHY DONOR

SCALABLE

MASS PRODUCED

1.

2.

APHERESIS

MANUFACTURING

ALLOGENEIC CAR-T

CANCER TREATMENT

OFF-THE-SHELF

OF 100+ DOSES/BATCH

THERAPIES

DECISION

CAR-T THERAPY

  • TIME SAVED
  • COST EFFECTIVE
  • MARKET ACCESS

P4

Pour lire la suite de ce noodl, vous pouvez consulter la version originale ici.

Disclaimer

Cellectis SA published this content on 12 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 November 2020 12:26:01 UTC


© Publicnow 2020
All news about CELLECTIS
01/14European ADRs Climb Higher in Thursday Trading
MT
01/13European ADRs Move Lower in Wednesday Trading
MT
01/11European ADRs Move Sharply Lower in Monday Trading
MT
01/08CELLECTIS : Corporate Presentation January 2021
PU
01/08European ADRs Nudge Higher in Friday Trading
MT
2020European ADRs Move Lower in Thursday Trading
MT
2020CELLECTIS : Monthly statement on outstanding equity shares and voting rights
CO
2020European ADRs Move Higher in Wednesday Trading
MT
2020European ADRs Move Higher in Monday Trading
MT
2020ALLOGENE THERAPEUTICS : Receives IND Clearance from the U.S. Food and Drug Admin..
AQ
More news
Financials
Sales 2020 53,4 M 64,8 M 64,8 M
Net income 2020 -74,3 M -90,1 M -90,1 M
Net cash 2020 161 M 195 M 195 M
P/E ratio 2020 -9,33x
Yield 2020 -
Capitalization 1 099 M 1 335 M 1 333 M
EV / Sales 2020 17,6x
EV / Sales 2021 15,2x
Nbr of Employees 259
Free-Float 83,2%
Chart CELLECTIS
Duration : Period :
Cellectis Technical Analysis Chart | ALCLS | FR0010425595 | MarketScreener
Technical analysis trends CELLECTIS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 27,35 €
Last Close Price 25,70 €
Spread / Highest target 13,6%
Spread / Average Target 6,42%
Spread / Lowest Target -0,78%
EPS Revisions
Managers and Directors
NameTitle
André Choulika Chief Executive Officer
Jean-Pierre Garnier Non-Executive Chairman
Eric Dutang Chief Financial Officer
Philippe Duchateau Chief Scientific Officer
Francisco J. Esteva Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
CELLECTIS5.33%1 335
MODERNA, INC.24.17%51 332
LONZA GROUP AG3.31%49 176
CELLTRION, INC.-1.81%43 849
IQVIA HOLDINGS INC.4.99%36 066
SEAGEN INC.0.41%31 812